Plain-English translation of NCT07481058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called given alongside an immunotherapy drug () and two standard chemotherapy medications ( and ) for people with advanced esophageal cancer that has spread or come back. The study wants to find the best dose of the medication and see how well this combination works to shrink tumors and help patients live longer. You would be one of about 60 people in the trial.
Advanced esophageal cancer is very serious and currently has limited treatment options. Doctors believe that combining this new medication with immunotherapy and chemotherapy may work better than existing treatments alone to fight the cancer and improve survival.
You likely qualify if…
You likely don't qualify if…
You would take as a daily oral pill, combined with intravenous injections of the immunotherapy drug and chemotherapy drugs given every 3 weeks. The first part of the trial (Phase IIa) tests different doses to find the safest level, and the second part (Phase IIb) randomizes patients to receive one of the selected doses. You would continue treatment until your cancer progresses, you experience unbearable side effects, or your doctor decides to stop treatment — with regular imaging scans and blood tests to monitor your response.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China